Skip to Content
Merck
  • Association of a functional FAAH polymorphism with methamphetamine-induced symptoms and dependence in a Malaysian population.

Association of a functional FAAH polymorphism with methamphetamine-induced symptoms and dependence in a Malaysian population.

Pharmacogenomics (2013-04-06)
Maw Shin Sim, Ahmad Hatim, Gavin Paul Reynolds, Zahurin Mohamed
ABSTRACT

FAAH is a membrane enzyme that terminates the activity of a large class of endogenous signaling lipids. Recent studies suggest that the FAAH Pro129Thr polymorphism is a common mutation in the FAAH gene that is significantly associated with drug-addictive traits. This study investigated the association of the Pro129Thr polymorphism of the FAAH gene with methamphetamine dependence, methamphetamine-induced psychosis, manic episodes and panic disorder in a Malaysian population. This polymorphism was genotyped in 232 male methamphetamine-dependent subjects and in 241 male controls of four different ethnicities: Malay, Chinese, Kadazan-Dusun and Bajau. Intergroup statistical analyses were performed by using the χ(2)-square test and Fisher's exact test, where necessary. In cases of multiple comparisons, the Bonferroni correction was performed. Our results indicated that the FAAH Pro129Thr polymorphism showed a significant association with risk of methamphetamine dependence in the pooled subjects (odds ratio [OR]: 2.017; p < 0.001) and in the Malay (OR: 2.829; p < 0.001) and Chinese (OR: 3.685; p < 0.001) groups. We also found an association of this polymorphism with episodes of methamphetamine-induced mania in the Malay group (OR: 2.836; p = 0.035). However, there was no association between this polymorphism and age of onset of drug use or the occurrence of methamphetamine-induced psychosis or of panic disorder. Our findings suggest that the FAAH Pro129Thr polymorphism may contribute to methamphetamine dependence in the Malay and Chinese ethnic groups.

MATERIALS
Product Number
Brand
Product Description

Supelco
S(+)-Methamphetamine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®